BlackRock Inc. increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,115,063 shares of the biopharmaceutical company’s stock after buying an additional 1,003,366 shares during the quarter. BlackRock Inc. owned about 7.24% of Alnylam Pharmaceuticals worth $903,969,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of ALNY. Orbimed Advisors LLC lifted its position in Alnylam Pharmaceuticals by 69.7% in the third quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock worth $127,453,000 after buying an additional 445,600 shares during the last quarter. Swiss National Bank lifted its position in Alnylam Pharmaceuticals by 136.8% in the fourth quarter. Swiss National Bank now owns 326,500 shares of the biopharmaceutical company’s stock worth $41,482,000 after buying an additional 188,600 shares during the last quarter. Kornitzer Capital Management Inc. KS bought a new stake in Alnylam Pharmaceuticals in the third quarter worth $19,131,000. Gilder Gagnon Howe & Co. LLC lifted its position in Alnylam Pharmaceuticals by 8.6% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 1,217,367 shares of the biopharmaceutical company’s stock worth $154,666,000 after buying an additional 96,812 shares during the last quarter. Finally, WINTON GROUP Ltd bought a new stake in Alnylam Pharmaceuticals in the third quarter worth $10,633,000. Institutional investors own 88.61% of the company’s stock.
In other Alnylam Pharmaceuticals news, SVP Laurie Keating sold 30,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $135.89, for a total value of $4,076,700.00. Following the transaction, the senior vice president now owns 41,500 shares in the company, valued at $5,639,435. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Michael Mason sold 36,745 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $131.59, for a total value of $4,835,274.55. Following the completion of the transaction, the vice president now owns 6,352 shares in the company, valued at approximately $835,859.68. The disclosure for this sale can be found here. Insiders sold 72,994 shares of company stock worth $9,669,353 in the last quarter. 4.30% of the stock is owned by insiders.
Alnylam Pharmaceuticals, Inc. (ALNY) opened at $121.42 on Friday. The company has a market capitalization of $11,970.16, a price-to-earnings ratio of -22.44 and a beta of 2.69. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.23 and a current ratio of 12.23. Alnylam Pharmaceuticals, Inc. has a 52 week low of $45.00 and a 52 week high of $147.63.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing the consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. The firm had revenue of $37.90 million for the quarter, compared to analysts’ expectations of $19.31 million. During the same quarter in the prior year, the business posted ($1.32) EPS. The business’s quarterly revenue was up 116.6% on a year-over-year basis. analysts forecast that Alnylam Pharmaceuticals, Inc. will post -6.88 EPS for the current year.
Several analysts have recently weighed in on ALNY shares. FBR & Co started coverage on Alnylam Pharmaceuticals in a research report on Monday, October 30th. They set a “buy” rating and a $150.00 target price for the company. B. Riley started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, November 1st. They set a “buy” rating and a $240.00 target price for the company. Piper Jaffray Companies reiterated an “overweight” rating and set a $14.71 target price (down from $188.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, November 2nd. Needham & Company LLC reiterated a “buy” rating and set a $152.00 target price (up from $125.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Finally, Cowen reiterated an “outperform” rating and set a $151.00 target price (up from $117.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $126.76.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/24/blackrock-inc-has-903-97-million-position-in-alnylam-pharmaceuticals-inc-alny.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.